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Abstract
Background: As an immune modulator, vitamin D is involved in various pathophysiological mechanisms in a
plethora of diseases. This study aims to correlate the vitamin D deficiency status and clinical progression of liver
diseases associated with hepatitis B virus (HBV) infection in patients in Vietnam and to compare it to healthy
controls.
Methods: We quantified the levels of total vitamin D [25-(OH) D2 and D3] in serum samples from 400 HBV patients
(chronic hepatitis B infection [CHB], n = 165; HBV-associated liver cirrhosis [LC], n = 127; HBV-associated
hepatocellular carcinoma [HCC], n = 108) and 122 unrelated healthy controls (HC). Univariate and multivariate
analyses were performed in order to determine the association between vitamin D levels and distinct clinical
parameters.
Results: The prevalence of vitamin D inadequacy (<30 ng/mL) was high among healthy individuals (81.7 %) as well
as in HBV patients (84.3 %). Vitamin D deficiency (<20 ng/ml) or severe deficiency (<10 ng/ml) was observed more
frequently among HBV patients (52 %) and subgroups (CHB, 47.8 %; LC, 54.4 %; HCC, 55.3 %) compared to the
control group (32.5 %) (P < 0.001). Vitamin D levels and HBV-DNA load were strongly and inversely correlated
(rho = −0.57, P < 0.0001). Multivariate regression analysis also revealed an independent association of HBV-DNA
loads with low vitamin D levels (P = 0.0004). In addition, reduced vitamin D levels were associated with
significant clinical progression of LC (Child-Pugh C versus Child-Pugh A, P = 0.0018; Child-Pugh C versus Child-Pugh B,
P = 0.016).
Conclusions: Vitamin D deficiency was observed in the majority of HBV-infected patients and associated with adverse
clinical outcomes. Our findings suggest that substitution of vitamin D may be a supportive option in the treatment of
chronic liver diseases, in particular of HBV-associated disorders.
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Background
Hepatitis B virus (HBV) infection is a major health prob-
lem which may be life-threatening due to it's frequent
severe complications, including fulminant acute hepa-
titis, liver cirrhosis (LC) and hepatocellular carcinoma
(HCC) [1]. Interactions between host immune responses
and HBV determine the clinical manifestations of HBV
infection. Innate immune mechanisms have important
roles in the clearance of HBV through production of
inflammatory cytokines such as interferons (IFN-α/β
and IFN-γ) [1].
Besides the classical function in regulating calcium and
bone homeostasis, vitamin D (cholecalciferol, 25-(OH)D3)
is also relevant in modulating both innate and adaptive
immune responses [2, 3]. Deficiency of vitamin D has
been shown to be involved in carcinogenesis and the
course of several infectious diseases [2–4], among them
distinct liver infections [5–8].
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In humans, vitamin D supplementation can result in
an increased activity of intrinsic IFN-α signaling [9] and
supplementation of vitamin D is a supportive option in
the treatment of pulmonary tuberculosis [10, 11].
Natural sources of vitamin D are mostly vitamin D3
(cholecalciferol) retrieved from nutrition and sunlight
exposure. Vitamin D2 is not produced in humans, and
small amounts of vitamin D2 (ergocalciferol) are derived
from edible plants [12]. Both vitamin D3 and D2 are
physiologically inactive. Hydroxylation occurs in the
liver, forming the intermediate metabolite (calcidiol, 25-
(OH)D). Calcidiol is further converted into the active
form (calcitriol, 1,25-(OH)2D) in the kidney [13] and
released in the circulation. Precise measurement of calci-
triol is intricate due to its low serum concentrations and
short half-life. Therefore, assessment of serum concen-
trations of both forms of 25-(OH)D3 and D2 are
required for the diagnosis of vitamin D deficiency [13].
Up to 90 % of vitamin D required for physiological func-
tions is derived from production and supply in the skin,
while the remainder is retrieved from the diet [14–16].
Production of vitamin D in the skin significantly depends
on sunshine exposure, geographical habitation and skin
pigmentation. However, vitamin D deficiency may occur
globally. In developed countries, vitamin D deficiency is
very common, with almost half of the population being
affected [13]. In Vietnam, a previous study has demon-
strated that vitamin D deficiency among women was
approximately 30 % and, thus, almost twice of that in men
(16 %) [17]. The prevalence of HBV infections currently
ranges from 10 to 20 % in the Vietnamese population and
HBV-related liver diseases are foreseen and predicted to
be a notable public health burden in the next decades
[18]. The present study aimed to study the association of
vitamin D deficiency status with the progression of HBV-
related liver diseases, including chronic hepatitis (CHB),
liver cirrhosis (LC) and hepatocellular carcinoma (HCC)
in Vietnam.
Methods
Subjects and sample collection
Four hundred Vietnamese HBV-infected patients were
enrolled for this cross-sectional study at the 108 Military
Central Hospital, Hanoi, Vietnam, between 2012 and
2014. HBV patients were assigned to the different clin-
ical subgroups based on clinical manifestations. Briefly,
CHB patients (n = 165) were characterized based upon
clinical symptoms such as fatigue, anorexia, jaundice,
hepatomegaly, hard density of the liver, splenomegaly,
hyperbilirubinemia, elevated levels of AST and ALT and
HBsAg positivity for more than 6 months. LC patients
(n = 127) were characterized as being infected with HBV
and presenting clinical manifestations such as anorexia,
nausea, vomiting, malaise, weight loss, abdominal distress,
jaundice, edema, cutaneous arterial spider angiomas, asci-
tes, shrunken liver, splenomegaly, hyperbilirubinemia,
elevated levels of AST and ALT, prolonged serum pro-
thrombin time, and decreased serum albumin. HCC pa-
tients (n = 108) were characterized as being infected
chronically with HBV and presenting abdominal pain, an
abdominal mass in the right upper quadrant, blood-tinged
ascites, weight loss, anorexia, fatigue, jaundice, prolonged
serum prothrombin time, hyperbilirubinemia, elevated
levels of AST, ALT and serum a-fetoprotein (AFP), ultra-
sound showing a tumor, and histopathology indicating
tumor cells. None of the patients had a history of alcohol
or drug abuse. HBV-DNA loads were measured by RT-
PCR using the 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, California, USA) and liver func-
tion tests, including assessment of alanine transaminase
(ALT) and aspartate transaminase (AST) enzyme levels,
alpha fetoprotein (AFP), platelet count (PLT), total and
direct bilirubin, albumin and prothrombin were per-
formed using AU640 Chemistry Analyzer (Beckman
Coulter, California, USA). Based on Child-Pugh scores,
HBV-related LC patients were categorized as Child-Pugh
A, −B and -C [19]. In addition, 122 healthy individuals de-
void of HBsAg were randomly enrolled from the hospital’s
blood bank as controls. None of these healthy individuals
had a history of any chronic liver disease, nor were they
immunosuppressed. All participants were confirmed nega-
tive for anti-HCV and anti-HIV antibodies by using com-
mercial ELISA assays (Diagnostic automation/Cortez
Diagnostics, Inc., Woodland Hills, California, USA).
Vitamin D measurement
Total vitamin D [25-(OH)D2 and D3] levels were mea-
sured in the serum samples from patients and controls
using a commercial ELISA kit (Gentaur, Kampenhout,
Belgium) according to the manufacturer’s instructions.
The kit’s range of vitamin D assessment is 4.39 to 133 ng/
ml with a coefficient of variation of 20 %. Based on the
recommendation of the Endocrine Society (Maryland,
USA; http://www.endocrine.org/) [20], a level of 30 ng/ml
or above is considered as vitamin D sufficiency. We,
therefore, categorized the vitamin D status as normal
(≥30 ng/ml), insufficient (20–29.9 ng/ml), deficient
(10–19.9 mg/ml), and severely deficient (<10 ng/ml).
Statistics
All statistical analyses were performed using R version
3.1.2 (http://www.r-project.org). Chi-square test, Kruskal-
Wallis test, and Mann-Whitney-Wilcoxon test were used
to compare differences between groups for qualitative or
quantitative variables where appropriate. Correlations be-
tween variables were evaluated using the Spearman’s rank
correlation test. We used univariate analyses, multivariate
logistic regression and multivariate linear regression
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models to test for associations of serum 25-(OH)D3 status
with clinical parameters and independent risk factors.
Bonferroni correction was applied as appropriate for
multiple comparisons. The level of significance was
set at P < 0.05.
Results
Patients and control characteristics
The baseline characteristics of the 400 HBV-infected pa-
tients and 122 healthy controls are given in Table 1. The
majority of both patients and healthy controls were
males (85.3 and 67.2 %, respectively). As expected, the
median age of patients increased with progression of
liver disease. Healthy controls were significantly younger
than patients (P < 0.001). The levels of ALT and AST
were significantly higher in patients with CHB compared
to those with LC and HCC (ALT: P < 0.001 and AST:
P = 0.014). As also expected, albumin and prothrom-
bin levels as well as platelet counts were significantly
lower in patients with LC compared to those without
LC (P < 0.01). AFP levels were significantly higher
among the HCC group compared to the CHB and LC
groups (P < 0.001).
Serum vitamin D levels in HBV infected patients and in
controls
Seven individuals, each two from the HC and the CHB
groups, and three from the HCC group had undetectable
vitamin D levels (<4.39 ng/ml). Vitamin D levels were
mostly inadequate (<30 ng/ml) in both HBV patients
(84.3 %) and controls (81.7 %); the difference, however,
was not significant. When vitamin D levels were strati-
fied into the four categories of normal levels (≥30 ng/
ml), insufficiency (20–29.9 ng/ml), deficiency (10–
19.9 mg/ml), and severe deficiency (<10 ng/ml), defi-
ciency and severe deficiency occurred frequently among
all HBV patients (51.9 %) and in all subgroups compared
to healthy controls (32.5 %) (P < 0.001) (Table 2).
Vitamin D levels were 20.7 ± 9.2 ng/ml in HBV-infected
patients and 23.6 ± 9.5 ng/ml in HCs. In the patient sub-
groups, vitamin D levels were 21.2 ± 8.9 ng/ml in CHB,
20.6 ± 10.4 ng/ml in LC, and 20 ± 8.3 ng/ml in HCC.
Vitamin D levels were higher in HCs than in HBV pa-
tients (HBV patients vs. HC: P = 0.0014; LC vs. HC: P =
0.0049; HCC vs. HC: P = 0.0028) (Fig. 1). Among the
HBV patients, vitamin D levels were decreased with pro-
gression of HBV-related liver diseases. However, signifi-
cant differences were not observed when comparing the
subgroups (CHB vs. LC, CHB vs. HCC and LC vs. HCC)
(Fig. 1). Deficiency and severe vitamin D deficiency were
significantly associated with advanced LC according to
Child-Pugh classifications (Fig. 2a and b). Of 127 LC
patients, 30.4 % patients of the Child-Pugh C group
had severe deficiency, while 10 % only in the Child-
Pugh A and B groups had severe deficiency (Fig. 2a).
In addition, vitamin D levels were significantly lower
Table 1 Characteristics of the study cohort
Characteristics CHB (n = 165) LC (n = 127) HCC (n = 108) HC (n = 122) P value
Age (median, range) 39 (18–79) 55 (19–84) 55 (18–81) 40 (19–58) <0.001
Gender (male/female) 135/30 107/20 99/9 82/40 <0.001
Liver cirrhosis stage:
Child-Pugh A (n, %) NA 42 (33.0 %) NA NA NA
Child-Pugh B (n, %) NA 62 (48.8 %) NA NA NA
Child-Pugh C (n, %) NA 23 (18.2 %) NA NA NA
WBC (×103/ml) 6.5 (3.6–13.9) 6.1 (1.8–20.5) 5.2 (2.1–15.1) NA 0.007
RBC (×106/ml) 4.9 (2.5–6.6) 3.6 (1.9–6.4) 4.2 (2.4–7.2) NA <0.001
PLT (×103/ml) 197.5 (21.5–472) 76.5 (24.4–641) 161 (6.7–428) NA <0.001
AST (IU/L) 100 (14–7700) 93 (26–1221) 53 (18–653) NA 0.014
ALT (IU/L) 120 (9–4908) 51.5 (8–1000) 43 (4–401) NA <0.001
Total-Bilirubin (mg/dl) 15.3 (6–499) 35.5 (6.4–733) 18 (9–185) NA <0.01
Direct-Bilirubin (mg/dl) 4.5 (1–300) 14.7 (1.6–449) 5.6 (1.1–156) NA <0.01
Albumin (g/L) 42 (16–53) 30 (16–54) 39.4 (22–47) NA <0.001
Prothrombin (%) 89 (41–140) 53.5 (14–101) 77.8 (20–127) NA <0.001
HBV-DNA (log10 copies/ml) 5.6 (2.4–10.1) NA NA NA NA
Alpha fetoprotein (IU/L) 2.7 (1.6–320) 9.2 (1.5–300) 196 (1.3–400) NA <0.001
Abbreviation: CHB chronic hepatitis B, LC liver cirrhosis, HCC hepatocellular carcinoma, HC healthy control, WBC white blood cells, RBC red blood cells, PLT platelets.
AST and ALT aspartate and alanine amino transferase, IU international unit, NA not applicable. Values given are medians and range. P values were calculated by
Chi-square test and Kruskal-Wallis test where appropriate
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in Child-Pugh C patients (15.1 ± 6.5 ng/ml), compared
to Child-Pugh B (20.8 ± 10.6 ng/ml) and Child-Pugh
A patients (23.3 ± 10.7 ng/ml) (P = 0.0018 and P =
0.016, respectively) (Fig. 2b).
Factors associated with vitamin D levels and vitamin D
deficiency
Of 165 CHB patients, 63 only were available for ana-
lyses of the correlation between vitamin D levels and
HBV-DNA loads. Vitamin D levels and HBV-DNA
were significantly and inversely correlated (rho =
−0.57, P < 0.0001) (Fig. 3). Other clinical parameters
were either not or weakly correlated with vitamin D
serum levels. This applied to the PLT (rho = 0.05),
ALT (rho = 0.16), AST (rho = 0.20), total-bilirubin
(rho = 0.03), direct-bilirubin (rho = 0.04), albumin (rho
= 0.002), AFP (rho = −0.02) and prothrombin levels
(rho = 0.07) (data not shown). We also performed
multivariate linear regression models to determine the
independent factors correlated with vitamin D levels.
Only HBV-DNA loads were independently and
inversely correlated with vitamin D levels (P = 0.0004)
(Table 3).
Next, we applied univariate analysis and multivariate
logistic regression models to assess the determinants
associated with vitamin D deficiency. HBV infection and
HBeAg negativity were independently associated with
low vitamin D levels (<30 ng/ml) in both univariate and
multivariate analyses. HCC was also a risk factor for low
vitamin D levels in the univariate analysis (Table 4).
Other independent factors such as age, gender, and the
occurrence of LC were not associated with any degree of
vitamin D deficiency.
Discussion
Vitamin D has not only important functions in the
metabolism of calcium and bone homeostasis but also
manifold effects in the fine regulation of immune
responses [2, 3, 13]. There is increasing evidence of vita-
min D deficiency effects on a wide spectrum of diseases,
including osteoporosis, autoimmunity, asthma, infec-
tious diseases, several forms of malignancy and even
psychiatric disorders [13, 21, 22]. This study shows that
insufficiency of vitamin D occurs more frequently
among healthy individuals as well as HBV patients. Vita-
min D levels were inversely correlated with HBV-DNA
loads and were associated with more severe conditions
of LC patients. These findings suggest that serum vita-
min D levels contribute significantly to the clinical
courses of HBV infection, including the severe conse-
quences of LC and HCC.
A high prevalence of vitamin D deficiency (>90 %) in
chronic liver disease has been reported to be associated
with liver disease progression [23–25]. High prevalence
of inadequate vitamin D status, as observed in both
healthy populations and in patients with HBV-related
liver diseases, indicate that low vitamin D levels are fre-
quent, along with osteoporosis in populations of many
geographical regions [13, 26]. Roughly, one billion people
worldwide apparently are vitamin D deficient [13, 27].
Table 2 Distribution of HBV-infected patients and healthy controls with Vitamin D status
Vitamin D
stratum
HC (n = 120) HBV patients (n = 395) CHB (n = 163) LC (n = 127) HCC (n = 105)
n (%) n (%) n (%) n (%) n (%)
Normal 22 (18.3) 62 (15.7) 29 (17.8) 24 (18.9) 9 (8.5)
Insufficiency 59 (49.2) 128 (32.4) 56 (34.3) 34 (26.7) 38 (36.2)
Deficiency 38 (31.7) 164 (41.5) 61 (37.4) 52 (41.0) 51 (48.6)
Severe deficiency 1 (0.8) 41 (10.4) 17 (10.4) 17 (13.4) 7 (6.7)
CHB chronic hepatitis B, LC liver cirrhosis, HCC hepatocellular carcinoma, HC healthy control, HBV hepatitis B virus
P = 0.00024 (Chi-square test for all groups including HC, CHB, LC, and HCC)
P = 0.00016 (Chi-square test: HBV patients vs. HC)
Fig. 1 Vitamin D levels in healthy individuals (HC), HBV patients and
subgroups. Chronic hepatitis B (CHB), liver cirrhosis (LC) and
hepatocellular carcinoma (HCC); P values were calculated by
Mann-Whitney Wilcoxon test
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Vitamin D deficiency occurs rather among the elderly
population [28, 29] and is more frequent in women
[13, 17]. In this study, the predominance of males in
all study groups and the significant difference in age
between cases and healthy individuals might influence
the degree of vitamin D deficiency between cases and
healthy individuals. In the multivariate analyses
adjusted for age and gender, HBV infection appears
to be an independent risk factor for vitamin D inad-
equacy that augments the risk for osteoporosis and
other vitamin D deficiency-related diseases. The high
prevalence of HBV infection in Vietnam (10–20 %)
[18] is an important factor favoring the occurrence of
osteoporosis and many other diseases related to vita-
min D deficiency.
In this study, deficiency and severe vitamin D defi-
ciency were observed more frequently in patients with
HBV-related liver disease and were found significantly
associated with the end-stage of liver cirrhosis (Child-
Pugh C). Vitamin D is involved in inhibition of
inflammation and abrogation of liver fibrosis, substan-
tiated by the observation that vitamin D receptor
knockout mice spontaneously develop hepatic fibrosis
[30, 31]. Apparently, vitamin D deficiency is a cause
of fibrosis progression [6, 8, 32]. The interaction
between vitamin D and its receptor can modulate the
immune response involved in the pathogenesis of
many solid cancers [33, 34]. Our study is in line with
previous studies which have indicated an association of
vitamin D levels with HCC [35–38]. Vitamin D can inhibit
the growth of HCC cell lines both in vitro and in vivo
[39], and supplementation of vitamin D and calcium has
substantially reduced the risk of cancer in a randomized
clinical trial [40]. In addition, vitamin D analogs and vita-
min D receptor activators such as maxacalcitol (OCT),
16-ene analogs, 19-nor analogs, LG190119 and C-20
cyclopropylcal-citriol have been developed and tested in a
pre-clinical study [41–43]. Vitamin D analogs and VDR
activators may in the future be promising adjuvants in
HCC treatment.
The causes of vitamin D deficiency in chronic liver
disease are considered multi-factorial [13, 21]. An
explanation for the low vitamin D levels observed in
chronic liver disease could be an impaired liver
function. Hepatic injuries lead to decreased produc-
tion of vitamin D carrier proteins such as vitamin D
binding protein and albumin, and impaired hepatic
hydroxylation of vitamin D to calcidiol or 25-(OH)D
in the liver. Vitamin D levels were shown to be
Fig. 2 Distribution of vitamin D levels in HBV related liver cirrhosis patients. a Vitamin D levels in different stages of HBV-related liver cirrhosis
according to Child-Pugh classification. b Vitamin D levels in different stages of HBV-related liver cirrhosis. Dot-plots illustrate medians with
interquartile ranges. P values were calculated by Mann-Whitney-Wilcoxon test
Fig. 3 Correlation between Vitamin D levels with HBV-DNA loads.
The correlation between vitamin D levels and HBV-DNA loads in
chronic hepatitis B patients was calculated by using Spearman’s rank
correlation coefficient. Spearman’s rho (rho) and P value are given
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positively correlated with albumin levels and platelet
counts and inversely correlated with ALT levels
during the active phase of chronic liver disease [6, 24, 25].
Serum vitamin D levels of <10 ng/ml can be a pre-
dictive factor for low serum albumin levels and the
severity of chronic liver disease [32, 44]. In the
present study, however, vitamin D inadequacy was
not significantly correlated with liver function param-
eters, possibly due to the fact that vitamin D serum
levels are affected by multiple factors and most of the
patients were not in the active phase during sample
collection.
In line with a previous study [45], our results cor-
roborate a strongly inverse correlation between HBV-
DNA loads and vitamin D levels. We assume that
vitamin D deficiency, as frequently observed in HBV
infection, can fail to suppress HBV replication. A link
between vitamin D deficiency and susceptibility to
various infections and the development of various
inflammatory diseases has been suggested [2, 3]. In
addition, low vitamin D levels linked to low sustained
virological response to interferon-based therapy in
chronic hepatitis B and C have been demonstrated in
clinical studies [8, 25]. Although vitamin D deficiency
is associated with adverse clinical outcomes of HBV
infection, our study has limitations. Serum vitamin D
levels are affected by several factors, including sea-
sonal variation, sunshine exposure, geographical habi-
tation and diet. However, any information concerning
the season at the time of sampling and diet of the
study subjects was not available. Another limitation is
that the study was a cross-sectional study and, thus,
we could not determine the fluctuation of vitamin D
levels over the course of HBV infection as well as the
causative association of vitamin D levels and HBV-
related liver diseases. Vitamin D may be an additional
factor for the clinical outcomes of HBV infection.
The influence of vitamin D metabolism on HBV-
related liver diseases remains unclear and the role of
vitamin D and its interaction with vitamin D receptor
on the pathogenesis of HBV infection needs to be
explored further.
Conclusions
Vitamin D deficiency was observed in the majority of
HBV patients particularly in advanced liver diseases and
associated with adverse clinical outcomes. Our findings
allow speculating that vitamin D and its analogs might
provide a potential therapeutic addendum in the treat-
ment of chronic liver diseases.
Table 3 Factors associated with baseline vitamin D levels in HBV patients
Variables Univariate analysis Multivariate analysis
P value P value Coefficient β
Age (continuous) 0.47 0.44 −0.07
Gender (male vs. female) 0.4 0.87 −0.49
HBeAg (positive vs. negative) 0.105 0.11 5.26
ALT levels (continuous) 0.08 0.51 0.008
HCC vs. non-HCC 0.019 0.13 7.5
Cirrhosis vs. non-cirrhosis 0.47 0.61 1.4
HBV-DNA (log10 copies/ml, continuous) <0.0001 0.0004 −1.9
Univariate analysis and multivariate linear regression model for independent factors were used to correlate vitamin D levels with clinical parameters. HBeAg
Hepatitis B envelope antigen, ALT alanine amino transferase, HCC hepatocellular carcinoma
Table 4 Univariate and multivariate logistic regression analyses of factors associated with vitamin D deficiency
Variables Univariate analysis Multivariate analysis
OR (95 % CI) P value OR (95 % CI) P value
HBV versus non-HBV (or HC) † 1.2 (0.7–2.0) 0.49 10.8 (1.4–81.8) 0.021
HCC versus non-HCC ‡ 2.4 (1.1–5.0) 0.029 2.4 (0.3–21.6) 0.43
Cirrhosis versus non-cirrhosis β 1.4 (0.8–2.5) 0.23 1.2 (0.5–2.7) 0.74
HBeAg (negative versus positive) γ 3.6 (1.2–10.7) 0.015 3.8 (1.2–12.0) 0.024
Univariate and multivariate logistic regression model for independent risk factors were applied. Independent risk factors added into the multivariate logistic
regression model are age, gender, HCC status, cirrhosis status and HBeAg status. (†), 395 HBV cases vs. 120 HC; (‡), 105 HCC cases vs. 290 non-HCC HBV patients;
(β), 127 LC patients vs. 268 non-cirrhosis HBV patients; (γ), 266 HBeAg negative vs. 129 HBeAg positive patients. HBV hepatitis B virus, HC healthy control, HBeAg
Hepatitis B envelope antigen, HCC hepatocellular carcinoma
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